Payload Information

General Information of This Payload
Payload ID
PAY0HAXGX
Name
Docetaxel
Synonyms
Docetaxel; 114977-28-5; Taxotere; Docetaxel anhydrous; Docetaxol; Docetaxel Winthrop; EmDOC; RP-56976; Docetaxolum; Docefrez; Taxoel; Docetaxel Kabi; Docetaxel [INN]; NSC 628503; Docetaxel, Trihydrate; N-debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol; RP 56976; taxotel; Docecad; DTXSID0040464; Docetaxel Teva; Docetaxel Accord; Taxotere(R); TXL; Taxotere (TN); Docetaxel, anhydrous; NSC-628503; UNII-699121PHCA; CHEBI:4672; DOCETAXEL MYLAN; Docetaxel hydrate; HSDB 6965; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol; 699121PHCA; Docetaxolum [INN-Latin]; DOCETAXEL TEVA PHARMA; docetere; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel; docetaxel 114977-28-5; DTXCID8020464; XRP-6976L; ANX-514; SDP-014; SID 530; Docetaxel (INN); NSC628503; N-debenzoyl-N-Boc-10-deacetyl taxol; CABAZITAXEL METABOLITE (RP56976); [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-1,9,12-trihydroxy-15-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate; Benzenepropanoic acid, beta-(((1,1-dimethylethoxy)carbonyl)amino)-alpha-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester; DOCETAXEL (USP-RS); UNII-15H5577CQD; Docetaxel intermediate; BIND 014; DOCETAXEL (EP MONOGRAPH); DOCETAXEL (USP IMPURITY); CKD-810; DOCETAXEL (USP MONOGRAPH); (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(acetyloxy)-15-{[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1,9,12-trihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0^{3,10}.0^{4,7}]heptadec-13-en-2-yl benzoate; (2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-acetoxy-9-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxet-12-yl benzoate; 4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate; Benzenepropanoic acid, beta-(((1,1-dimethylethoxy)carbonyl)amino)-alpha-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (alphaR,betaS)-; CAS-114977-28-5; NSC 759850; DOCETAXEL TRIHYDRATE (EP MONOGRAPH); docetaxelum; C43H53NO14; MFCD00871399; Docetaxel (TN); Docetaxel- Bio-X; NCGC00181306-01; NCGC00181306-02; 4-(acetyloxy)-13alpha-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate; Taxotere (Aventis); CID148124; Docetaxolum (Latin); Docetaxel - Taxotere; RP56976; bind-014; Docetaxel (JAN/INN); DOCETAXEL [JAN]; DOCETAXEL [MI]; CHEMBL92; DOCETAXEL [HSDB]; Benzenepropanoic acid, beta-(((1,1-dimethylethoxy)carbonyl)amino)-alpha-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,1313-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, trihydrate, (alphaR,betaS)-; D0O5WP; Taxotere/Docetaxel Winthrop; SCHEMBL4419; N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol; GTPL6809; BIND 014 [WHO-DD]; BDBM36351; SYP-0704A; ZDZOTLJHXYCWBA-VCVYQWHSSA-; AMY4356; L01CD02; ZDZOTLJHXYCWBA-VCVYQWHSSA-N; 114977-28-5, Docetaxel; HMS2089K08; EX-A1206; HY-B0011; Tox21_112781; Tox21_113088; AC-383; DOCETAXEL ANHYDROUS [WHO-DD]; AKOS015960718; AKOS024457953; C43-H53-N-O14; Tox21_112781_1; CS-1144; CS-O-11300; DB01248; KS-1452; Docetaxel, purum, >=97.0% (HPLC); NCGC00181306-04; NCGC00242509-01; BD164373; D4102; D07866; EN300-123047; AB01273941-01; AB01273941-02; Q420436; SR-01000003023; W-60384; Q-100074; SR-01000003023-5; BRD-K30577245-001-04-3; BRD-K30577245-341-01-9; Z1546621742; Anhydrous Docetaxel, European Pharmacopoeia (EP) Reference Standard; (1S,2S,3R,4S,5R,7S,8S,10R,13S)-4-Acetoxy-2-benzoyloxy-5,20-epoxy-1,7,10-trihydroxy-9-oxotax-11-en-13-yl (2R,3S)-3-(1,1-dimethylethyl)oxycarbonylamino-2-hydroxy-3-phenylpropanoate; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate; (2R,3S)-N-CARBOXY-3-PHENYLISOSERINE, N-TERT-BUTYL ESTER, 13-ESTER WITH 5.BETA.,20-EPOXY-1,2.ALPHA.,4,7.BETA.,10.BETA.,13.ALPHA.-HEXAHYDROXYTAX-11-EN-9-ONE 4-ACETATE 2-BENZOATE; (2R,3S)-N-CARBOXY-3-PHENYLISOSERINE, N-TERT-BUTYL ESTER, 13-ESTER WITH 5beta,20-EPOXY-1,2alpha,4,7beta,10beta,13alpha-HEXAHYDROXYTAX-11-EN-9-ONE 4-ACETATE 2-BENZOATE; [2aR-[2a?,4?,4a?,6?,9?(?R*,?S*),11?,12?,12a?,12b?]]-?-[[(1,1-Dimethylethoxy)carbonyl]amino]-?-hydroxy-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester benzenepropanoic acid; [acetoxy-[(2R,3S)-3-(tert-butoxycarbonylamino)-2-hydroxy-3-phenyl-propanoyl]oxy-trihydroxy-tetramethyl-oxo-[?]yl] benzoate; 114915-20-7; Benzenepropanoic acid, beta-(((1,1-dimethylethoxy)carbonyl)amino)-alpha-hydroxy-, (2aR,4S,4aR,6R,9S,11S,12S,12aS,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,4a,6,11-tetrahydroxy-8,12a,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (alphaR)-, hydrate (1:3); Benzenepropanoic acid,1-dimethylethoxy)carbonyl]amino]-.alpha.-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (.alpha.R,.beta.S)
   Click to Show/Hide
Target(s) Microtubule (MT)
 Target Info 
Structure
Formula
C43H53NO14
Isosmiles
CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O
PubChem CID
148124
InChI
InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1
InChIKey
ZDZOTLJHXYCWBA-VCVYQWHSSA-N
IUPAC Name
[(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-1,9,12-trihydroxy-15-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
Pharmaceutical Properties
Molecule Weight
807.9
Polar area
224
Complexity
1660
xlogp Value
1.6
Heavy Count
58
Rot Bonds
13
Hbond acc
14
Hbond Donor
5
The activity data of This Payload
Standard Type Value Units Cell line Disease Model Cell line ID Reference
Half Maximal Cell Growth Inhibitory Concentration (GI50) 0.006 ug/mL
22RV1 cells
Prostate carcinoma
CVCL_1045 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 0.009 ug/mL
PC-3 cells
Prostate carcinoma
CVCL_0035 
[1]
Half Maximal Inhibitory Concentration (IC50) 5 ug/mL
DU145 cells
Prostate carcinoma
CVCL_0105 
[2]
Half Maximal Inhibitory Concentration (IC50) 0.1 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[3]
Half Maximal Inhibitory Concentration (IC50) 0.1 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[4]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 0.13 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[5]
Half Maximal Inhibitory Concentration (IC50) 0.2 nM
LNCaP cells
Prostate carcinoma
CVCL_0395 
[6]
Half Maximal Inhibitory Concentration (IC50) 0.2 nM
LNCaP cells
Prostate carcinoma
CVCL_0395 
[7]
Half Maximal Inhibitory Concentration (IC50) 0.3 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[8]
Half Maximal Inhibitory Concentration (IC50) 0.4 nM
Calu-1 cells
Lung squamous cell carcinoma
CVCL_0608 
[8]
Half Maximal Inhibitory Concentration (IC50) 0.5 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[3]
Half Maximal Inhibitory Concentration (IC50) 0.5 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[4]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 0.5 nM
MV4-11 cells
Childhood acute monocytic leukemia
CVCL_0064 
[9]
Half Maximal Inhibitory Concentration (IC50) 0.5 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[8]
Half Maximal Inhibitory Concentration (IC50) 0.6 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[8]
Half Maximal Inhibitory Concentration (IC50) 0.6 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[10]
Half Maximal Inhibitory Concentration (IC50) 0.7 nM
U-251MG cells
Astrocytoma
CVCL_0021 
[8]
Half Maximal Inhibitory Concentration (IC50) 0.75 nM
SK-OV-3 cells (FZD7 overexpression)
Ovarian serous cystadenocarcinoma
CVCL_0532 
[11]
Half Maximal Inhibitory Concentration (IC50) 1.2 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[6]
Half Maximal Inhibitory Concentration (IC50) 1.2 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[7]
Half Maximal Inhibitory Concentration (IC50) 1.7 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[12]
Half Maximal Inhibitory Concentration (IC50) 1.7 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[13]
Half Maximal Inhibitory Concentration (IC50) 1.8 nM
SH-SY5Y cells
Bone marrow neuroblastoma
CVCL_0019 
[10]
Half Maximal Inhibitory Concentration (IC50) 1.9 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[6]
Half Maximal Inhibitory Concentration (IC50) 1.9 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[7]
Half Maximal Inhibitory Concentration (IC50) 10 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[14]
Half Maximal Inhibitory Concentration (IC50) 10 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[15]
Half Maximal Inhibitory Concentration (IC50) 10 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[14]
Half Maximal Inhibitory Concentration (IC50) 10.3 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[16]
Half Maximal Inhibitory Concentration (IC50) 11.2 nM
A2780 cells
Ovarian endometrioid adenocarcinoma
CVCL_0134 
[17]
Half Maximal Inhibitory Concentration (IC50) 11.8 nM
MM1.S cells
Plasma cell myeloma
CVCL_8792 
[12]
Half Maximal Inhibitory Concentration (IC50) 110 nM
HEK293 cells
Normal
CVCL_0045 
[14]
Half Maximal Inhibitory Concentration (IC50) 116540 nM
CCD-18Co cells
Normal
CVCL_2379 
[18]
Half Maximal Inhibitory Concentration (IC50) 12.5 nM
DND-41 cells
T acute lymphoblastic leukemia
CVCL_2022 
[12]
Half Maximal Inhibitory Concentration (IC50) 127 nM
P388 cells
Lymphoma
CVCL_7222 
[19]
Half Maximal Inhibitory Concentration (IC50) 129.8 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[20]
Half Maximal Inhibitory Concentration (IC50) 13 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[21]
Half Maximal Inhibitory Concentration (IC50) 130 nM
Vero cells
Normal
CVCL_0059 
[14]
Half Maximal Inhibitory Concentration (IC50) 13000 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[22]
Half Maximal Inhibitory Concentration (IC50) 14.2 nM
Z-138 cells
Mantle cell lymphoma
CVCL_B077 
[12]
Half Maximal Inhibitory Concentration (IC50) 15.2 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[12]
Half Maximal Inhibitory Concentration (IC50) 1530.5 nM
NCI-ADR-RES cells
High grade ovarian serous adenocarcinoma
CVCL_1452 
[13]
Half Maximal Inhibitory Concentration (IC50) 16 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[23]
Half Maximal Inhibitory Concentration (IC50) 1680 nM
L132 cells
Endocervical adenocarcinoma
CVCL_1908 
[24]
Half Maximal Inhibitory Concentration (IC50) 17.5 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[25]
Half Maximal Inhibitory Concentration (IC50) 1730 nM
RWPE-1 cells
Normal
CVCL_3791 
[21]
Half Maximal Inhibitory Concentration (IC50) 19 nM
Capan-1 cells
Pancreatic ductal adenocarcinoma
CVCL_0237 
[23]
Half Maximal Inhibitory Concentration (IC50) 19.5 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[25]
Half Maximal Inhibitory Concentration (IC50) 1940 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[26]
Half Maximal Inhibitory Concentration (IC50) 19700 nM
HEK293 cells
Normal
CVCL_0045 
[18]
Half Maximal Inhibitory Concentration (IC50) 2 nM
LN-229 cells
Glioblastoma
CVCL_0393 
[27]
Half Maximal Inhibitory Concentration (IC50) 2 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[19]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 2 nM
SK-MEL19 cells
Melanoma
CVCL_6025 
[9]
Half Maximal Inhibitory Concentration (IC50) 2.4 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[12]
Half Maximal Inhibitory Concentration (IC50) 2.7 nM
T84 cells
Colon adenocarcinoma
CVCL_0555 
[28]
Half Maximal Inhibitory Concentration (IC50) 20 nM
SW620 cells
Colon adenocarcinoma
CVCL_0547 
[18]
Half Maximal Inhibitory Concentration (IC50) 210 nM
WPMY-1 cells
Normal
CVCL_3814 
[10]
Half Maximal Inhibitory Concentration (IC50) 22 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[21]
Half Maximal Inhibitory Concentration (IC50) 2340 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[7]
Half Maximal Inhibitory Concentration (IC50) 25 nM
Capan-1 cells
Pancreatic ductal adenocarcinoma
CVCL_0237 
[27]
Half Maximal Inhibitory Concentration (IC50) 25000 nM
TERT-RPE1 cells
Normal
CVCL_4388 
[26]
Half Maximal Inhibitory Concentration (IC50) 26 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[21]
Half Maximal Inhibitory Concentration (IC50) 27.9 nM
PC3/DX cells
Prostate carcinoma
CVCL_C3M5 
[3]
Half Maximal Inhibitory Concentration (IC50) 2860 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[24]
Half Maximal Inhibitory Concentration (IC50) 3.5 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[17]
Half Maximal Inhibitory Concentration (IC50) 3.5 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[18]
Half Maximal Inhibitory Concentration (IC50) 3.55 nM
A2780-1A9 cells
Ovarian adenocarcinoma
CVCL_H619 
[29]
Half Maximal Inhibitory Concentration (IC50) 3000 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[26]
Half Maximal Inhibitory Concentration (IC50) 3000 nM
Z-138 cells
Mantle cell lymphoma
CVCL_B077 
[26]
Half Maximal Inhibitory Concentration (IC50) 32 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[21]
Half Maximal Inhibitory Concentration (IC50) 3230 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[24]
Half Maximal Inhibitory Concentration (IC50) 3410 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[24]
Half Maximal Inhibitory Concentration (IC50) 352.3 nM
DU145-TxR cells
Prostate carcinoma
CVCL_ZX03 
[3]
Half Maximal Inhibitory Concentration (IC50) 3600 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[24]
Half Maximal Inhibitory Concentration (IC50) 38 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[16]
Half Maximal Inhibitory Concentration (IC50) 39 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[21]
Half Maximal Inhibitory Concentration (IC50) 4 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[23]
Half Maximal Inhibitory Concentration (IC50) 4 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[28]
Half Maximal Inhibitory Concentration (IC50) 4 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[27]
Half Maximal Inhibitory Concentration (IC50) 4 nM
Z-138 cells
Mantle cell lymphoma
CVCL_B077 
[27]
Half Maximal Inhibitory Concentration (IC50) 4.7 nM
SW620 cells
Colon adenocarcinoma
CVCL_0547 
[28]
Half Maximal Inhibitory Concentration (IC50) 4.95 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[30]
Half Maximal Inhibitory Concentration (IC50) 4000 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[22]
Half Maximal Inhibitory Concentration (IC50) 410 nM
NCI-ADR-RES cells
High grade ovarian serous adenocarcinoma
CVCL_1452 
[19]
Half Maximal Inhibitory Concentration (IC50) 43.25 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[30]
Half Maximal Inhibitory Concentration (IC50) 47 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[23]
Half Maximal Inhibitory Concentration (IC50) 5 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[31]
Half Maximal Inhibitory Concentration (IC50) 5 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[32]
Half Maximal Inhibitory Concentration (IC50) 50 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[27]
Half Maximal Inhibitory Concentration (IC50) 50 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[14]
Half Maximal Inhibitory Concentration (IC50) 55.3 nM
TERT-RPE1 cells
Normal
CVCL_4388 
[12]
Half Maximal Inhibitory Concentration (IC50) 60 nM
HEp-2 cells
Laryngeal carcinoma
CVCL_1906 
[14]
Half Maximal Inhibitory Concentration (IC50) 61 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[21]
Half Maximal Inhibitory Concentration (IC50) 680 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[10]
Half Maximal Inhibitory Concentration (IC50) 7 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[27]
Half Maximal Inhibitory Concentration (IC50) 7 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[23]
Half Maximal Inhibitory Concentration (IC50) 7 nM
P388 cells
Lymphoma
CVCL_7222 
[19]
Half Maximal Inhibitory Concentration (IC50) 7.2 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[12]
Half Maximal Inhibitory Concentration (IC50) 7.3 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[13]
Half Maximal Inhibitory Concentration (IC50) 70 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[14]
Half Maximal Inhibitory Concentration (IC50) 70 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[14]
Half Maximal Inhibitory Concentration (IC50) 734 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[13]
Half Maximal Inhibitory Concentration (IC50) 8 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[31]
Half Maximal Inhibitory Concentration (IC50) 8.8 nM
Capan-1 cells
Pancreatic ductal adenocarcinoma
CVCL_0237 
[12]
Half Maximal Inhibitory Concentration (IC50) 800 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[33]
Half Maximal Inhibitory Concentration (IC50) 8300 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[34]
Half Maximal Inhibitory Concentration (IC50) 836.2 nM
A549/TR cells
Lung adenocarcinoma
CVCL_C5S0 
[25]
Half Maximal Inhibitory Concentration (IC50) 8580 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[7]
Half Maximal Inhibitory Concentration (IC50) 860 nM
HEY cells
Ovarian carcinoma
CVCL_0297 
[11]
Half Maximal Inhibitory Concentration (IC50) 890 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[26]
Half Maximal Inhibitory Concentration (IC50) 9 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[27]
Half Maximal Inhibitory Concentration (IC50) 9 nM
Z-138 cells
Mantle cell lymphoma
CVCL_B077 
[23]
Half Maximal Inhibitory Concentration (IC50) 9.8 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[13]
Half Maximal Inhibitory Concentration (IC50) 90 nM
SiHa cells
Cervical squamous cell carcinoma
CVCL_0032 
[14]
Half Maximal Inhibitory Concentration (IC50) 950 nM
Capan-1 cells
Pancreatic ductal adenocarcinoma
CVCL_0237 
[26]
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
Docetaxel-trastuzumab [Investigative]
 ADC Info 
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [35]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 60.00% (Day 67) Positive HER2 expression (HER2 +++/++)
Method Description
Docetaxel and trastuzumab (5 and 1.9 mg/kg, respectively,every seven days 3) induces efficient tumor cell killing in cell line-derived models of SKBR3 cells with HER2 expression with high expression.
In Vivo Model SKBR-3 CDX model
In Vitro Model Breast adenocarcinoma SK-BR-3 cells CVCL_0033
MM-310 [Terminated in phase 1]
 ADC Info 
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [36]
Related Clinical Trial
NCT Number NCT03076372  Phase Status Phase 1
Clinical Description
A phase-1 study evaluating the safety, pharmacology and preliminary activity of MM-310 in patients with solid tumors.
References
Ref 1 Synthesis of novel 4-Boc-piperidone chalcones and evaluation of their cytotoxic activity against highly-metastatic cancer cells. Bioorg Med Chem Lett. 2020 Jan 1;30(1):126760. doi: 10.1016/j.bmcl.2019.126760. Epub 2019 Oct 28.
Ref 2 Isoxazole derivatives as anticancer agent: A review on synthetic strategies, mechanism of action and SAR studies. Eur J Med Chem. 2021 Oct 5;221:113511. doi: 10.1016/j.ejmech.2021.113511. Epub 2021 May 6.
Ref 3 Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy. J Med Chem. 2018 Feb 22;61(4):1704-1718. doi: 10.1021/acs.jmedchem.7b01858. Epub 2018 Feb 12.
Ref 4 Structure-Guided Design, Synthesis, and Biological Evaluation of (2-(1H-Indol-3-yl)-1H-imidazol-4-yl)(3,4,5-trimethoxyphenyl) Methanone (ABI-231) Analogues Targeting the Colchicine Binding Site in Tubulin. J Med Chem. 2019 Jul 25;62(14):6734-6750. doi: 10.1021/acs.jmedchem.9b00706. Epub 2019 Jul 12.
Ref 5 New MKLP-2 inhibitors in the paprotrain series: Design, synthesis and biological evaluations. Bioorg Med Chem. 2016 Feb 15;24(4):721-34. doi: 10.1016/j.bmc.2015.12.042. Epub 2015 Dec 24.
Ref 6 Optimized synthesis and antiproliferative activity of desTHPdactylolides. Bioorg Med Chem. 2018 Jul 23;26(12):3514-3520. doi: 10.1016/j.bmc.2018.05.026. Epub 2018 May 18.
Ref 7 An amide mimic of desTHPdactylolide: Total synthesis and antiproliferative evaluation. Bioorg Med Chem Lett. 2021 May 15;40:127970. doi: 10.1016/j.bmcl.2021.127970. Epub 2021 Mar 19.
Ref 8 Antiproliferative Cardenolides from the Aerial Parts of Pergularia tomentosa. J Nat Prod. 2019 Jan 25;82(1):74-79. doi: 10.1021/acs.jnatprod.8b00630. Epub 2019 Jan 10.
Ref 9 Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors. Eur J Med Chem. 2019 Apr 15;168:87-109. doi: 10.1016/j.ejmech.2019.02.022. Epub 2019 Feb 19.
Ref 10 Echiumin E, an Aryl Dihydronaphthalene Lignan from the Australian Invasive Plant Paterson's Curse (Echium plantagineum). J Nat Prod. 2022 Oct 28;85(10):2474-2479. doi: 10.1021/acs.jnatprod.2c00151. Epub 2022 Sep 20.
Ref 11 Taxol Analogues Exhibit Differential Effects on Photoaffinity Labeling of -Tubulin and the Multidrug Resistance Associated P-Glycoprotein. J Nat Prod. 2018 Mar 23;81(3):600-606. doi: 10.1021/acs.jnatprod.7b01047. Epub 2018 Mar 8.
Ref 12 N-substituted benzimidazole acrylonitriles as in?vitro tubulin polymerization inhibitors: Synthesis, biological activity and computational analysis. Eur J Med Chem. 2021 Feb 5;211:113003. doi: 10.1016/j.ejmech.2020.113003. Epub 2020 Nov 7.
Ref 13 Synthesis and biological evaluation of novel larotaxel analogues. Eur J Med Chem. 2018 Aug 5;156:692-710. doi: 10.1016/j.ejmech.2018.07.029. Epub 2018 Jul 20.
Ref 14 Lupane-Type Triterpenes of Phoradendron vernicosum. J Nat Prod. 2017 Nov 22;80(11):3038-3042. doi: 10.1021/acs.jnatprod.7b00177. Epub 2017 Nov 9.
Ref 15 Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved?. Eur J Med Chem. 2021 Jan 15;210:112948. doi: 10.1016/j.ejmech.2020.112948. Epub 2020 Oct 23.
Ref 16 Metabolomics-Driven Discovery of Meroterpenoids from a Mussel-Derived Penicillium ubiquetum. J Nat Prod. 2018 Nov 26;81(11):2501-2511. doi: 10.1021/acs.jnatprod.8b00569. Epub 2018 Nov 8.
Ref 17 A Series of Enthalpically Optimized Docetaxel Analogues Exhibiting Enhanced Antitumor Activity and Water Solubility. J Nat Prod. 2018 Mar 23;81(3):524-533. doi: 10.1021/acs.jnatprod.7b00857. Epub 2018 Jan 23.
Ref 18 Novel octapeptide-DTX prodrugs targeting MMP-7 as effective agents for the treatment of colorectal cancer with lower systemic toxicity. Eur J Med Chem. 2020 May 1;193:112194. doi: 10.1016/j.ejmech.2020.112194. Epub 2020 Feb 28.
Ref 19 SureChEMBL: a large-scale, chemically annotated patent document database. Nucleic Acids Res. 2016 Jan 4;44(D1):D1220-8. doi: 10.1093/nar/gkv1253. Epub 2015 Nov 17.
Ref 20 Berchemiosides A-C, 2-Acetoxy--phenylpentaene Fatty Acid Triglycosides from the Unripe Fruits of Berchemia berchemiifolia. J Nat Prod. 2017 Oct 27;80(10):2778-2786. doi: 10.1021/acs.jnatprod.7b00602. Epub 2017 Oct 3.
Ref 21 Novel Benzo[a]quinolizidine Analogs Induce Cancer Cell Death through Paraptosis and Apoptosis. J Med Chem. 2016 May 26;59(10):5063-76. doi: 10.1021/acs.jmedchem.6b00484. Epub 2016 May 11.
Ref 22 Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents. Bioorg Med Chem. 2017 Jan 15;25(2):545-556. doi: 10.1016/j.bmc.2016.11.026. Epub 2016 Nov 15.
Ref 23 Xylo-C-nucleosides with a pyrrolo[2,1-f][1,2,4]triazin-4-amine heterocyclic base: Synthesis and antiproliferative properties. Bioorg Med Chem Lett. 2019 Jun 15;29(12):1450-1453. doi: 10.1016/j.bmcl.2019.04.023. Epub 2019 Apr 15.
Ref 24 Design, synthesis and biological evaluation of 1,3,6-trisubstituted -carboline derivatives for cytotoxic and anti-leishmanial potential. Bioorg Med Chem Lett. 2016 Feb 1;26(3):789-794. doi: 10.1016/j.bmcl.2015.12.095. Epub 2015 Dec 29.
Ref 25 Synthesis and biological evaluation of novel cabazitaxel analogues. Bioorg Med Chem. 2021 Jul 1;41:116224. doi: 10.1016/j.bmc.2021.116224. Epub 2021 May 23.
Ref 26 Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives. Bioorg Med Chem. 2019 Mar 15;27(6):1023-1033. doi: 10.1016/j.bmc.2019.02.005. Epub 2019 Feb 2.
Ref 27 Synthesis and Antitumor Activity of C-7-Alkynylated and Arylated Pyrrolotriazine C-Ribonucleosides. ACS Med Chem Lett. 2020 Jul 9;11(8):1605-1610. doi: 10.1021/acsmedchemlett.0c00269. eCollection 2020 Aug 13.
Ref 28 Neothalfine, a potent natural anti-tumor agent against metastatic colorectal cancer and its primary mechanism. Bioorg Med Chem. 2021 Jan 1;29:115849. doi: 10.1016/j.bmc.2020.115849. Epub 2020 Nov 8.
Ref 29 Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry. J Med Chem. 2018 Mar 22;61(6):2166-2210. doi: 10.1021/acs.jmedchem.7b00315. Epub 2017 Sep 8.
Ref 30 Design and synthesis of -naphthoflavone chimera derivatives able to eliminate cytochrome P450 (CYP)1B1-mediated drug resistance via targeted CYP1B1 degradation. Eur J Med Chem. 2020 Mar 1;189:112028. doi: 10.1016/j.ejmech.2019.112028. Epub 2020 Jan 2.
Ref 31 Brefeldin A enhances docetaxel-induced growth inhibition and apoptosis in prostate cancer cells in monolayer and 3D cultures. Bioorg Med Chem Lett. 2017 Jun 1;27(11):2286-2291. doi: 10.1016/j.bmcl.2017.04.047. Epub 2017 Apr 17.
Ref 32 Design and evaluation of 1,2,3-dithiazoles and fused 1,2,4-dithiazines as anti-cancer agents. Bioorg Med Chem Lett. 2021 Jul 1;43:128078. doi: 10.1016/j.bmcl.2021.128078. Epub 2021 May 2.
Ref 33 neo-Clerodane diterpenoids from Scutellaria barbata mediated inhibition of P-glycoprotein in MCF-7/ADR cells. Eur J Med Chem. 2016 Oct 4;121:238-249. doi: 10.1016/j.ejmech.2016.05.045. Epub 2016 May 24.
Ref 34 Cytotoxic Ceanothane- and Lupane-Type Triterpenoids from the Roots of Ziziphus jujuba. J Nat Prod. 2016 Sep 23;79(9):2364-75. doi: 10.1021/acs.jnatprod.6b00525. Epub 2016 Sep 12.
Ref 35 Tumor uptake and associated greater efficacy of anti-Her2 immunoliposome does not rely on Her2 expression status: study of a docetaxel-trastuzumab immunoliposome on Her2+ breast cancer model (SKBR3). Anticancer Drugs. 2020 Jun;31(5):463-472. doi: 10.1097/CAD.0000000000000878.
Ref 36 A Phase-1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of MM-310 in Patients With Solid Tumors

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.